Research ExplorerPublicationsHistory of thyroid disease and survival of ovarian cancer pa...

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

Standard

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. / Minlikeeva, Albina N; Freudenheim, Jo L; Cannioto, Rikki A; Eng, Kevin H; Szender, J Brian; Mayor, Paul; Etter, John Lewis; Cramer, Daniel W; Diergaarde, Brenda; Doherty, Jennifer A; Dörk, Thilo; Edwards, Robert; deFazio, Anna; Friel, Grace; Goodman, Marc T; Hillemanns, Peter; Høgdall, Estrid; Jensen, Allan; Jordan, Susan J; Karlan, Beth Y; Kjær, Susanne K; Klapdor, Rüdiger; Matsuo, Keitaro; Mizuno, Mika; Nagle, Christina M; Odunsi, Kunle; Paddock, Lisa; Rossing, Mary Anne; Schildkraut, Joellen M; Schmalfeldt, Barbara; Segal, Brahm H; Starbuck, Kristen; Terry, Kathryn L; Webb, Penelope M; Zsiros, Emese Z; Ness, Roberta B; Modugno, Francesmary; Bandera, Elisa V; Chang-Claude, Jenny; Moysich, Kirsten B.

In: BRIT J CANCER, Vol. 117, No. 7, 26.09.2017, p. 1063-1069.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Minlikeeva, AN, Freudenheim, JL, Cannioto, RA, Eng, KH, Szender, JB, Mayor, P, Etter, JL, Cramer, DW, Diergaarde, B, Doherty, JA, Dörk, T, Edwards, R, deFazio, A, Friel, G, Goodman, MT, Hillemanns, P, Høgdall, E, Jensen, A, Jordan, SJ, Karlan, BY, Kjær, SK, Klapdor, R, Matsuo, K, Mizuno, M, Nagle, CM, Odunsi, K, Paddock, L, Rossing, MA, Schildkraut, JM, Schmalfeldt, B, Segal, BH, Starbuck, K, Terry, KL, Webb, PM, Zsiros, EZ, Ness, RB, Modugno, F, Bandera, EV, Chang-Claude, J & Moysich, KB 2017, 'History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report', BRIT J CANCER, vol. 117, no. 7, pp. 1063-1069. https://doi.org/10.1038/bjc.2017.267

APA

Minlikeeva, A. N., Freudenheim, J. L., Cannioto, R. A., Eng, K. H., Szender, J. B., Mayor, P., Etter, J. L., Cramer, D. W., Diergaarde, B., Doherty, J. A., Dörk, T., Edwards, R., deFazio, A., Friel, G., Goodman, M. T., Hillemanns, P., Høgdall, E., Jensen, A., Jordan, S. J., ... Moysich, K. B. (2017). History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. BRIT J CANCER, 117(7), 1063-1069. https://doi.org/10.1038/bjc.2017.267

Vancouver

Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender JB, Mayor P et al. History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. BRIT J CANCER. 2017 Sep 26;117(7):1063-1069. https://doi.org/10.1038/bjc.2017.267

Bibtex

@article{99bfd27431d84635ab01630a65494fac,
title = "History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report",
abstract = "BACKGROUND: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.METHODS: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.RESULTS: Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.CONCLUSIONS: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.British Journal of Cancer advance online publication: 17 August 2017; doi:10.1038/bjc.2017.267 www.bjcancer.com.",
keywords = "Journal Article",
author = "Minlikeeva, {Albina N} and Freudenheim, {Jo L} and Cannioto, {Rikki A} and Eng, {Kevin H} and Szender, {J Brian} and Paul Mayor and Etter, {John Lewis} and Cramer, {Daniel W} and Brenda Diergaarde and Doherty, {Jennifer A} and Thilo D{\"o}rk and Robert Edwards and Anna deFazio and Grace Friel and Goodman, {Marc T} and Peter Hillemanns and Estrid H{\o}gdall and Allan Jensen and Jordan, {Susan J} and Karlan, {Beth Y} and Kj{\ae}r, {Susanne K} and R{\"u}diger Klapdor and Keitaro Matsuo and Mika Mizuno and Nagle, {Christina M} and Kunle Odunsi and Lisa Paddock and Rossing, {Mary Anne} and Schildkraut, {Joellen M} and Barbara Schmalfeldt and Segal, {Brahm H} and Kristen Starbuck and Terry, {Kathryn L} and Webb, {Penelope M} and Zsiros, {Emese Z} and Ness, {Roberta B} and Francesmary Modugno and Bandera, {Elisa V} and Jenny Chang-Claude and Moysich, {Kirsten B}",
year = "2017",
month = sep,
day = "26",
doi = "10.1038/bjc.2017.267",
language = "English",
volume = "117",
pages = "1063--1069",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

AU - Minlikeeva, Albina N

AU - Freudenheim, Jo L

AU - Cannioto, Rikki A

AU - Eng, Kevin H

AU - Szender, J Brian

AU - Mayor, Paul

AU - Etter, John Lewis

AU - Cramer, Daniel W

AU - Diergaarde, Brenda

AU - Doherty, Jennifer A

AU - Dörk, Thilo

AU - Edwards, Robert

AU - deFazio, Anna

AU - Friel, Grace

AU - Goodman, Marc T

AU - Hillemanns, Peter

AU - Høgdall, Estrid

AU - Jensen, Allan

AU - Jordan, Susan J

AU - Karlan, Beth Y

AU - Kjær, Susanne K

AU - Klapdor, Rüdiger

AU - Matsuo, Keitaro

AU - Mizuno, Mika

AU - Nagle, Christina M

AU - Odunsi, Kunle

AU - Paddock, Lisa

AU - Rossing, Mary Anne

AU - Schildkraut, Joellen M

AU - Schmalfeldt, Barbara

AU - Segal, Brahm H

AU - Starbuck, Kristen

AU - Terry, Kathryn L

AU - Webb, Penelope M

AU - Zsiros, Emese Z

AU - Ness, Roberta B

AU - Modugno, Francesmary

AU - Bandera, Elisa V

AU - Chang-Claude, Jenny

AU - Moysich, Kirsten B

PY - 2017/9/26

Y1 - 2017/9/26

N2 - BACKGROUND: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.METHODS: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.RESULTS: Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.CONCLUSIONS: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.British Journal of Cancer advance online publication: 17 August 2017; doi:10.1038/bjc.2017.267 www.bjcancer.com.

AB - BACKGROUND: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.METHODS: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.RESULTS: Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19-3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.CONCLUSIONS: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.British Journal of Cancer advance online publication: 17 August 2017; doi:10.1038/bjc.2017.267 www.bjcancer.com.

KW - Journal Article

U2 - 10.1038/bjc.2017.267

DO - 10.1038/bjc.2017.267

M3 - SCORING: Journal article

C2 - 28817835

VL - 117

SP - 1063

EP - 1069

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 7

ER -